Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT02119468
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2014-07-22Est. Completion: 2016-05-18
Enrollment target: 32 participants Locations- Mayo Clinic, Scottsdale, Arizona, United States
- City of Hope Medical Center, Duarte, California, United States
- Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Relapsed/Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in vario…
Birmingham, United StatesEst. completion Nov 2026
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD…
New York, United StatesEst. completion Aug 1, 2028